Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 8/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | SLC13A5 | Q86YT5 | 2/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | SLC13A2 | Q13183 | 1/20 | 0.37 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | CCR8 | P51685 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10084731 | 0.84 | ACHE (0.44) | PIK3CACYP3A4SLC13A5MKNK1MKNK2 | |
| SCHEMBL12093598 | 0.80 | PIK3CA (0.44) | PIK3CACYP3A4MAPTPIK3R1MTOR | |
| SCHEMBL14329387 | 0.79 | SLC13A5 (0.40) | PIK3CACYP3A4SLC13A5CCR1CCR5 | |
| SCHEMBL24174272 | 0.79 | CYP3A4 (0.34) | PIK3CACYP3A4SLC13A5SLC13A2SLC13A3 | |
| SCHEMBL15849049 | 0.78 | PIK3CA (0.42) | PIK3CAMAPTPIK3R1CCR1CCR5 | |
| SCHEMBL24174271 | 0.78 | GAA (0.38) | PIK3CACYP3A4CCR1CCR5CCR8 | |
| SCHEMBL24048533 | 0.78 | ALOX5AP (0.36) | PIK3CACYP3A4CCR1CCR5CCR8 | |
| SCHEMBL17987114 | 0.78 | DHODH (0.39) | PIK3CACYP3A4CCR1CCR5CCR8 | |
| SCHEMBL12093552 | 0.77 | NOS3 (0.48) | PIK3CASLC13A5MKNK1MKNK2SLC13A2 | |
| SCHEMBL29823245 | 0.77 | NOS3 (0.48) | PIK3CASLC13A5MKNK1MKNK2SLC13A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771738-B2 | Endoparasitic depsipeptides | ZOETIS SERVICES LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-11771738-B2 | Endoparasitic depsipeptides | ZOETIS SERVICES LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | X-CHEM GLOBAL HQ | 2023-06-29 | — | — | US | disclosed |
| WO-2023067322-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2023-04-27 | — | — | WO | disclosed |
| US-20220220104-A1 | PYRAZOLOPYRIDINE COMPOUND AS RET INHIBITOR AND APPLICATION THEREOF | GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD. BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY (CN) | 2022-07-14 | — | — | US | disclosed |
| EP-3950685-A1 | PYRAZOLOPYRIDINE COMPOUND AS RET INHIBITOR AND APPLICATION THEREOF | Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory (CN) | 2022-02-09 | — | — | EP | disclosed |
| WO-2022002097-A1 | PYRAZOLO[1,5-A]PYRIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海艾力斯医药科技股份有限公司 | 2022-01-06 | — | — | WO | disclosed |
| EP-3612536-B1 | OXEPINOPYRAZOLE DERIVATIVES AS INHIBITORS OF PI3-KINASE ACTIVITY | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-12-15 | — | — | EP | disclosed |
| EP-3845531-A1 | SUBSTITUTED PYRAZOLE FUSED RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Applied Pharmaceutical Science, Inc. (CN) | 2021-07-07 | — | — | EP | disclosed |
| US-7378418-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378418-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-7335656-B2 | Stent with a disposed traiazine compound such as 6-(3-Chloro-4-methoxy-phenoxy)-N-cycloheptyl-N'-methyl-N'-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4-diamine for inhibiting smooth muscle proliferation; restenosis and atherosclerosis | REDDY US THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335770-B2 | Triazine compounds and their analogs, compositions, and methods | REDDY U5 THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7332489-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332490-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| WO-2007134828-A1 | PYRAZOLO [3, 4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | NOVARTIS AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| EP-1697371-B1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2007-04-25 | — | — | EP | disclosed |
| EP-1697370-B1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2007-04-25 | — | — | EP | disclosed |
| US-7169785-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | PIK3CA 884/4885CYP3A4 1831/4885SLC13A5 4362/4885 |
| US-11771738-B2 | Endoparasitic depsipeptides | VIP, PREP, VIPR1 | PIK3CA 2033/4885CYP3A4 3009/4885SLC13A5 1616/4885 |
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1A, SCN3A, SCN2A | PIK3CA 1530/4885CYP3A4 319/4885SLC13A5 165/4885 |
| US-20220220104-A1 | PYRAZOLOPYRIDINE COMPOUND AS RET INHIBITOR AND APPLICATION THEREOF | RET, BRAF, RAF1 | PIK3CA 464/4885CYP3A4 4244/4885SLC13A5 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.